Gain Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
GANX$1.09+5.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Changes in Stockholders’ Equity
| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Stock · · APIC · AOCI · · Accumulated · · Total | ||||||||||||
| · Shares · Amounts · · · Deficit · | ||||||||||||
| Balance as of December 31, 2022 | 11,883,368 | $1,189 | $57,358,895 | $35,627 | $(38,516,197) | $18,879,514 | ||||||
| Stock-based compensation (Note 15) | 171,751 | 16 | 3,305,056 | — | — | 3,305,072 | ||||||
| Defined benefit pension plan (Note 11) | | — | — | (127,601) | — | (127,601) | ||||||
| Foreign currency translation | | — | — | 249,911 | — | 249,911 | ||||||
| Net unrealized gain on available for sale securities (Note 5) | | | | — | | — | | 89,304 | | — | | 89,304 |
| Issuance of shares in at-the-market (ATM) offering (Note 14) | | 862,535 | | 86 | | 3,544,790 | | — | | — | | 3,544,876 |
| Issuance of shares and warrants in public offering and private placement (Note 14) | | 3,289,026 | | 330 | | 8,904,338 | | — | | — | | 8,904,668 |
| Net loss | | | | — | | — | | — | | (22,267,520) | | (22,267,520) |
| Balance as of December 31, 2023 | 16,206,680 | 1,621 | 73,113,079 | 247,241 | (60,783,717) | 12,578,224 | ||||||
| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Stock · · APIC · · AOCI · · Accumulated · · Total | ||||||||||||
| · Shares · Amounts · · · Deficit · | ||||||||||||
| Balance as of December 31, 2021 | | 11,883,368 | $1,189 | $55,832,461 | $(90,645) | $(20,925,459) | $34,817,546 | |||||
| Stock-based compensation (Note 15) | | | | — | | 1,526,434 | | — | | — | | 1,526,434 |
| Defined benefit pension plan (Note 11) | | | | — | | — | | 227,131 | | — | | 227,131 |
| Foreign currency translation | | | | — | | — | | (6,580) | | — | | (6,580) |
| Net unrealized gain on available for sale securities (Note 5) | | | | — | | — | | (94,279) | | — | | (94,279) |
| Net loss | | | | — | | — | | — | | (17,590,738) | | (17,590,738) |
| Balance as of December 31, 2022 | | 11,883,368 | | 1,189 | | 57,358,895 | | 35,627 | | (38,516,197) | | 18,879,514 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.